Success Story: Bioengineering Ph.D. Candidate from Taiwan Secures NIW Approval for Work Advancing Gene and Cell Therapy Production
Client’s Testimonial:
"Thanks for all of the help."
On July 1st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Ph.D. Candidate in the Field of Bioengineering (Approval Notice).
General Field: Bioengineering
Position at the Time of Case Filing: Ph.D. Candidate
Country of Origin: Taiwan
State of Residence at the Time of Filing: Texas
Approval Notice Date: July 1st, 2026
Processing Time: 2 months, 18 days (Premium Processing Requested)
Case Summary:
Expanding access to advanced medical therapies depends not only on scientific discovery, but also on the ability to produce those therapies more efficiently and affordably. The client’s work addresses this need through advanced bioengineering research focused on novel biomolecular structures and scalable purification platforms. These frameworks are designed to support the highly efficient, lower-cost production of advanced cellular and gene therapies, an area directly connected to urgent public health needs involving the treatment of complex, chronic, and genetic diseases.
At the time of filing, the client was a Ph.D. candidate and had already earned an M.S. in materials science and engineering. North America Immigration Law Group (Chen Immigration Law Associates) emphasized how the client’s background supported a coherent research direction. We explained how the client’s expertise could help improve therapeutic manufacturing.
The petition also highlighted the client’s strong research record, including:
- 7 peer-reviewed journal articles, 1 patent application, and 1 published patent
- 225 citations to the client’s published work
These credentials were not presented as numbers alone. We explained how the client’s publications, patent activity, and citation record showed that the client had produced methods and findings that other researchers had relied upon in advancing related bioengineering studies.
To further establish the client’s ability to advance the proposed endeavor, the petition detailed how independent researchers had actively utilized the client’s findings in downstream studies involving advanced biomaterials, tissue engineering, and targeted nanotherapeutics. These examples demonstrated that the client’s foundational contributions had already shaped subsequent research in bioengineering and translational medicine.
This NIW approval reflected the value of connecting a specialized bioengineering record to broader national interests in public health, biotechnology, and therapeutic accessibility. We are pleased that our firm could assist in presenting the client’s credentials, research impact, and future plans in a clear and persuasive manner, and we congratulate the client on this approval.